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Abstract 
Background 
One-third of breast cancers display amplifications of the ERBB2 gene encoding the HER2 
kinase receptor. Trastuzumab, a humanized antibody directed against an epitope on 
subdomain IV of the extracellular domain of HER2 is used for therapy of HER2-
overexpressiong mammary tumors. However, many tumors are either natively resistant or 
acquire resistance against Trastuzumab. Antibodies directed to different epitopes on the 
extracellular domain of HER2 are promising candidates for replacement or combinatorial 
therapy. For example, Pertuzumab that binds to subdomain II of HER2 extracellular domain 
and inhibits receptor dimerization is under clinical trial. Alternative antibodies directed to 
novel HER2 epitopes may serve as additional tools for breast cancer therapy. Our aim was to 
generate novel anti-HER2 monoclonal antibodies inhibiting the growth of breast cancer cells, 
either alone or in combination with tumor necrosis factor-α (TNF-α). 
Methods 
Mice were immunized against SK-BR-3 cells and recombinant HER2 extracellular domain 
protein to produce monoclonal antibodies. Anti-HER2 antibodies were characterized with 
breast cancer cell lines using immunofluorescence, flow cytometry, immunoprecipitation, 
western blot techniques. Antibody epitopes were localized using plasmids encoding 
recombinant HER2 protein variants. Antibodies, either alone or in combination with TNF-α, 
were tested for their effects on breast cancer cell proliferation. 
Results 
We produced five new anti-HER2 monoclonal antibodies, all directed against conformational 
epitope or epitopes restricted to the native form of the extracellular domain. When tested 
alone, some antibodies inhibited modestly but significantly the growth of SK-BR-3, BT-474 
and MDA-MB-361 cells displaying ERBB2 amplification. They had no detectable effect on 
MCF-7 and T47D cells lacking ERBB2 amplification. When tested in combination with TNF-
α, antibodies acted synergistically on SK-BR-3 cells, but antagonistically on BT-474 cells. A 
representative anti-HER2 antibody inhibited Akt and ERK1/2 phosphorylation leading to 
cyclin D1 accumulation and growth arrest in SK-BR-3 cells, independently from TNF-α. 
Conclusions 
Novel antibodies against extracellular domain of HER2 may serve as potent anti-cancer 
bioactive molecules. Cell-dependent synergy and antagonism between anti-HER2 antibodies 
and TNF-α provide evidence for a complex interplay between HER2 and TNF-α signaling 
pathways. Such complexity may drastically affect the outcome of HER2-directed therapeutic 
interventions. 
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Background 
With a lifetime risk of ~12%, breast cancer is the most common cancer in women [1]. 
Although the survival rates of breast cancer patients are increasing due to the recently 
developed therapeutic approaches, breast cancer remains the most frequent cause of cancer-
related death in women [2]. More than 225,000 new cases of female-breast cancer are 
estimated to occur in 2012, in the United States alone, and 40,000 female deaths are expected 
as a result [3]. 25-30% of breast cancers display HER2 overexpression [4]. ERBB2 gene 
amplification that was discovered in the early 1980s is the main cause of HER2 
overexpression [5]. HER2 is a tyrosine kinase receptor belonging to the ErbB/HER family 
that also includes epidermal growth factor receptor (EGFR/HER1), ErbB3/HER3 and 
ErbB4/HER4. HER2 displays tyrosine kinase activity, but has no known ligand. ErbB family 
receptors are activated by homodimerization or heterodimerization. HER2 is activated either 
by ligand-independent homodimerization when it is overexpressed, or by heterodimerization 
with a ligand-dependent ErbB/HER member, in particular with ErbB3/HER3 [6]. 
Following the discovery of ERBB2 gene amplifications in breast cancer, the HER2 receptor 
became an attractive target for monoclonal antibody-based therapies. Trastuzumab is the first 
clinically approved humanized monoclonal antibody targeting HER2. It produced 11-26% 
overall response rates as monotherapy for metastatic breast cancer. In addition, as adjuvant to 
chemotherapy, Trastuzumab significantly increased disease-free and overall survival in both 
early stage and metastatic breast cancers. Trastuzumab is effective only in HER2-
amplified/overexpressing tumors and primary resistance to therapy is a challenge [7]. 
Moreover, the majority of metastatic breast cancer patients who initially respond to 
Trastuzumab begin to demonstrate disease progression again within 1 year [8]. Trastuzumab 
resistance was linked to many factors, including the overexpression of other ErbB/HER 
family receptors and/or their ligands [9,10], insulin-like growth factor receptors [11,12], 
MUC4 [13] and soluble extracellular domain (ECD) of HER2 circulating in the blood 
[14,15], activating PI3K mutations [16], PTEN deletions [17], downregulation of cyclin-
dependent kinase inhibitor p27 [18] and increased Akt activity [19,20]. 
HER2-HER3 heterodimer is known to be the most potent activated form of HER2 in terms of 
strength of interaction, ligand-induced tyrosine phosphorylation and down-stream signaling. 
Indeed, HER3 might be a necessary partner for HER2-mediated oncogenic activity in HER2-
overexpressing tumors [6]. The ECD of HER2 is composed of four subdomains and 
Trastuzumab is directed to its subdomain IV [21]. The antibody inhibits HER2 activation [6], 
but cannot prevent HER2-HER3 heterodimerization [22]. Pertuzumab is another antibody 
directed to another epitope that is located at subdomain II, which is involved in receptor 
dimerization [23]. It appears to be more effective than Trastuzumab, in particular in low 
HER2-expressing tumor cells because of its ability to interfere with HER2-HER3 
heterodimerization [23]. Pertuzumab and Trastuzumab were shown to act synergistically 
against breast cancer cell survival [24], suggesting that antibodies against different epitopes 
of the ECD are able to generate not only additive but also synergistic cellular responses. The 
limited efficacy of Trastuzumab for cancer therapy, problems of acquired resistance and the 
potential impact of novel anti-HER2 antibodies as therapeutic partners or alternative 
therapeutics justify more investment on HER2 targeting with novel monoclonal antibodies. 
Here, we describe five novel monoclonal antibodies directed against an epitope (or epitopes) 
restricted to the native conformation of HER2 ECD. In vitro studies provide evidence for 
anti-cancer activity of these antibodies. More interestingly, these novel antibodies appear to 
interact with tumor necrosis factor-α (TNF-α) in a cell-dependent manner, generating both 
synergistic and antagonistic growth responses. 
Methods 
Reagents 
A disulfide-linked homodimer of histidine-tagged extracellular domain of HER2 fused to 
human IgG1 Fc domain (HER2 ECD), a similar construct based on EGFR extracellular 
domain (EGFR ECD), and IgG1 isotype control antibody were from R&D Systems (MN, 
USA). Alkaline phosphatase (AP)- and horseradish peroxidase (HRP)-conjugated secondary 
antibodies to mouse and human IgGs, propidium iodide, trichloroacetic acid (TCA), 
Sulforhodamine B (SRB), Incomplete Freund’s Adjuvant, anti-calnexin antibody (#C4731), 
p-nitrophenyl phosphate, disodium salt (PNPP), 4', 6-diamidino-2-phenylindole (DAPI), 
insulin and Bromodeoxyuridine (BrdU) were from Sigma Aldrich (MO, USA). Anti-HER2 
CB11antibody (#ab8054) was from Abcam (MA, USA). Anti-BrdU antibody (#M0744) was 
from Dako (Glostrup, Denmark). Anti-Akt (#9272), anti-phospho-Akt (#9271), anti-Erk 1/2 
(#9107), anti-phospho-Erk 1/2 (#9106) antibodies were from Cell Signaling (MA, USA). 
Anti-phospho-HER2 (#sc-1011694) and anti-Cyclin D1 (#sc-246) antibodies were from 
Santa Cruz (California, USA). Alexa Fluor 488-conjugated secondary antibodies to mouse 
and human IgGs and Lipofectamine 2000 were from Invitrogen (CA, USA). HiTrap Protein 
G HP columns and ECL plus western blot detection kit were from GE-Healthcare (WI, USA). 
Recombinant human TNF-α was from PeproTech (NJ, USA). RNAse A and all restriction 
enzymes were from Fermentas (Vilnius, Lithuania). Trastuzumab (Herceptin), EDTA-free 
protease inhibitor cocktail tablets and phosSTOP (phosphatase inhibitor cocktail) tablets were 
from Roche Ltd (Basel, Switzerland). Antibody isotyping kit was from Thermo Fisher 
Scientific Inc (IL, USA). Protein G coupled Sepharose gel slurry was from East Coast 
Biologics (ME, USA). 
Cell culture 
SK-BR-3, MDA-MB-361, T47D, MCF-7 and BT-474 cell lines were obtained from ATCC. 
Huh-7 cell line is used in lab since 1995 and was last tested for authenticity in 2010 
(originally from Jack Wands Lab at Massachusetts General Hospital, Boston, MA). All breast 
cancer cell lines have been tested and authenticated by short tandem repeat profiling in 
September 2009 and February 2012, as described previously [25]. SK-BR-3 cells were grown 
in McCoy’s 5A medium. MDA-MB-361, T47D, MCF-7, BT-474 and Huh-7 cells were 
grown in Dulbecco’s Modified Eagle Medium (DMEM), as described [25,26]. Hybridomas 
were grown in RPMI 1640, DMEM or Serum Free Media (SFM) from Hyclone (IL, USA). 
Cell culture media were purchased from GIBCO (CA, USA), Sigma or Hyclone, and were 
supplemented with 10% fetal calf serum (FCS), 1% penicillin/streptomycin (P/S), 1% non-
essential amino acids and 1% L-glutamine, unless otherwise stated. BT-474 cell growth 
medium was supplemented additionally with 10 μg/ml insulin. 
Fluorescent in situ hybridization analysis of ERBB2 copy numbers 
MCF-7, T47D, MDA-MB-361, SK-BR-3 and BT-474 cells were harvested at confluence and 
fixed in Carnoy’s fixative (3:1 methanol/glacial acetic acid). A dual-color FISH was 
performed with Texas Red-labeled ERBB2 and FITC-labeled chromosome 17 α-satellite 
(D17Z1) DNA probes mix (LPS 001; Cytocell Ltd, Cambridge, UK), as described by supplier 
with minor modifications. The slides were treated at 72°C for 2 min in denaturation solution 
containing 70% formamide, 2XSSC (3 M NaCl, 0.3 M sodium citrate, pH 7.0). The probe 
mixture was applied onto slides; the area was covered with a 22X22 mm glass coverslip, 
sealed with rubber cement. Slides were placed on a hot plate and heated at 75°C for 5 min. 
The hybridization was done overnight at 37°C in humidified chambers. Post-hybridization 
washes were done once with 0.4XSSC at 72°C for 2 min and once with 2XSSC containing 
0.05% Tween 20, at room temperature for 30 s. After post-hybridization washes, the slides 
were dehydrated in a series of 70%, 85%, and 97% ethanol. Air-dried slides were 
counterstained with 4,6-diamidino-2-phenylindole (DAPI) in an anti-fade solution. Copy 
numbers in >100 nuclei of each cell line were counted under a Nikon Eclipse E600 
epifluorescence microscope (Nikon Corp., Tokyo, Japan) equipped with filter sets 
appropriate for DAPI, FITC, and rhodamine. Individual single-color images of DAPI, FITC, 
and rhodamine were acquired through a high-sensitivity monochrome charge-coupled device 
(CCD) camera integrated to a Power Macintosh. Digitally acquired individual images were 
overlaid and operated with MacProbe image analysis software (PCI Scientific Systems 
League City, TX, USA). ERBB2 copy numbers and ploidy level based on average counts of 
centromere 17 in interphase and metaphase FISH were evaluated according to international 
standard cytogenetic nomenclature [27]. 
Generation of anti-HER2 monoclonal antibodies 
Animal experiments described here have been pre-approved by the Bilkent University 
Animal Experiments Ethical Review Panel, and conducted at Bilkent Animal House, which is 
certified by the Ministry of Agriculture of Turkey. All procedures complied with the 
guidelines of the Ministry of Agriculture (Official Gazette. No. 25464). BALB/c mice were 
immunized five times with live SK-BR-3 cells (5–10 × 106 cells in PBS) by intra-peritoneal 
injection at three-week intervals. As a final booster, each mouse received 20 μg recombinant 
HER2 ECD protein injected with incomplete Freund’s adjuvant. On the third day of last 
immunization, mice were sacrificed and their splenocytes were fused with SP2/O myeloma 
cells to produce hybridomas as previously described [28]. 
HER2 ECD ELISA assay 
96-well Polysorb (NUNC, Roskilde, Denmark) microtiter plates were coated overnight at 4°C 
with HER2-ECD (25–50 ng/well) in carbonate buffer. Following saturation with 1% BSA for 
one hour, plates were incubated with hybridoma supernatants or purified primary antibodies 
for 2–4 h, and bound antibodies were detected by further incubation with AP-conjugated anti-
mouse IgG antibodies. Trastuzumab binding was tested using AP-conjugated anti-human IgG 
antibodies. Phosphatase activity was measured using PNPP substrate with absorbance (OD) 
reading at 405 nm using μQuant ELISA reader (BioTek, VT USA). The cross-reactivity tests 
with EGFR ECD were performed under the same conditions, except that ELISA plates were 
coated with EGFR ECD. 
Antibody isotyping and affinity purification 
The isotypes of monoclonal antibodies were determined using a commercial kit. Selected 
hybridoma clones were expanded and the antibodies were purified from the culture 
supernatants by FPLC using HiTrap Protein G HP columns (GE Healthcare, WI, USA). 
Immunofluorescence 
Cells were seeded on coverslips in 6-well plates. After 36 h of cell culture, they were fixed 
with 2% paraformaldehyde and permeabilized with 0.1% Triton X-100. Following saturation 
with 10% FCS, the fixed cells were incubated with anti-HER2 antibodies for 90 min. Primary 
antibody binding was detected using Alexa Fluor 488 conjugated goat anti-mouse IgG or 
Alexa Fluor 488 conjugated goat anti-human IgG antibodies, depending on the type of the 
primary antibody. Nuclei were counterstained with DAPI and cells were observed using Zeiss 
Axio Imager.A1 microscope (Jena, Germany). 
Flow Cytometry 
Cells (3-5×10
5) were fixed with 2% paraformaldehyde and incubated 1 h with 5 μg/ml anti-
HER2 antibodies or IgG1 isotype control antibody (in 1% BSA and 0.5 mg/ml NaN3 in PBS). 
Cells were then incubated 1 h with Alexa-488-conjugated anti-mouse IgG antibody and the 
percentage of positively stained cells were counted on FACSCalibur (BD Biosciences). 
Immunoprecipitation 
For detection of endogenous HER2 protein, cells were lysed in RIPA buffer (150 mM NaCl, 
50 mM Tris–HCl pH; 7.4, 1 mM EDTA, 1% Triton X-100, 1% Na-deoxycholate, 0.1% SDS, 
1X Protease Inhibitors) [29,30], 2 mg protein were diluted with milder NP40 buffer (150 mM 
NaCl, 50 mM Tris–HCl pH: 8, 1% NP40, 1X Protease Inhibitors) and incubated with 20 μg 
antibody for 2 h on a rotator at 4°C. Then, 200 μl Protein G-coupled Sepharose gel slurry was 
added, and the mixture was incubated 4 h at 4°C. 
Western blot 
Following immunoprecipitation experiments, antigen-antibody bound Protein G beads were 
boiled in SDS-loading buffer; solubilized proteins were run on 8% or 4-12% gradient SDS-
PAGE. Proteins subjected to SDS-PAGE were transferred to PVDF membrane using XCell II 
Blot Module (Invitrogen, CA, USA). Unoccupied protein binding sites on the PVDF 
membrane were saturated by incubating with 5% dried milk (in TBS-T) for 1 h. Full length 
and truncated forms of HER2 protein were detected using CB11 antibody directed against 
intracellular domain. Briefly, membranes were incubated overnight with CB11 antibody 
(1/500 dilution), followed by 1 h incubation with HRP-conjugated secondary antibodies to 
mouse IgGs and bound antibody was detected using ECL plus western blot detection kit. 
Epitope mapping 
The experiment was based on testing of antibody binding to HER2 proteins that have been 
modified by deletion of different subdomains of its ECD. Mammalian expression plasmids 
were constructed and transiently transfected into Huh-7 cells. Antibody binding was tested by 
combined immunoprecipitation-western blot and indirect immunofluorescence assays. A 
pDEST26-derived plasmid vector expressing full-length human HER2 protein 
(OCABo5050G0219D; shortly called p219D here) was obtained from Source BioScience 
LifeSciences (Nottingham, UK). HER2 extracellular domain was extracted from p219D by 
Sac I/Eco RI digestion leaving the coding sequence for the N-terminal 22 amino acid signal 
peptide intact. pCC2001 was produced by inserting Not I and Xho I sites between this 
sequence and the sequence encoding the rest of HER2 protein starting from the 
transmembrane domain. DNA sequences allowing the inclusion of domains I, II, III and IV of 
ECD under different combinations were amplified by PCR and inserted into pCC2001 
plasmid using the Not I and Xho I sites. The integrity of cloned sequences has been verified 
by DNA sequencing. Huh-7 cells (6×10
5
) were transfected in 6-well plates with different 
HER2 plasmid constructs (5 μg each) using Lipofectamine 2000, following a protocol 
provided by the manufacturer. Following 8-h Lipofectamine incubation, cells were washed 
with PBS and incubated overnight with fresh complete media (without P/S). Next day, the 
cells were trypsinized and replated. On the second day of cell-expansion, the cells were 
collected, lysed in RIPA buffer and subjected to immunoprecipitation and western blot 
analyses as described above, except that 150 μg proteins were immunoprecipitated using 15 
μg antibody. 
Cell growth assay 
This assay was performed as described previously [31]. Briefly, cells (10
3
) were seeded in 
96-well plates in triplicate and allowed to attach by 2 h of preincubation. Antibodies were 
diluted in cell culture medium and added to preincubated cells to obtain 0–20 μg/ml 
concentrations under a final volume of 200 μl medium/well. Cells were then incubated up to 
6 days. TNF-α treatment was performed similarly except that cells were preincubated for 6 h. 
For antibody and TNF-α co-treatment experiments and checkerboard assays, cells were 
preincubated for 2 h for attachment, followed by 4-h incubation with antibodies prior to TNF-
α addition. At the end of each time point, culture supernatants were discarded. Attached cells 
were washed twice with PBS, fixed with ice-cold 10% TCA for one hour, followed by 
Sulforhodamine B-based reading, as described [32]. 
Drug interaction modeling 
Drug interaction scores for pairwise combinations of TNF-α with individual antibodies at 
fixed concentrations were calculated as follows. Growth level in a drug condition was defined 
as the growth measurement in the drug condition normalized by growth measurement under 
no drug. To understand the interaction between an antibody and TNF-α at certain 
concentrations, growth levels under single antibody, TNF-α, antibody + TNF-α were 
compared. Expected growth level under no drug interaction was defined for each pairwise 
drug combination as the multiplication of the growth levels under each individual drug, 
following the Bliss Independence Model for drug interactions [33]. The observed growth 
level for each combination was divided by the expected growth level to find an interaction 
score. According to this analysis, a score of 1 means no interaction, or independence, a score 
smaller than 1 means synergy, and a score larger than 1 means antagonism. For the drug 
interaction experiments where more than one concentration combination was experimentally 
tested, a single interaction score between two drugs was computed. For this, a modified 
version of the above algorithm and the data from all concentration combinations was used, as 
described previously [34]. The scores and the scale of these scores are equivalent to the single 
combination drug interaction experiment and are interpreted in the same way (<1 = synergy; 
>1 = antagonism). Each interaction experiment was done in triplicate, and the average growth 
levels were used for interaction score calculation. 
Bromodeoxyuridine incorporation assay 
Cells (10
4
) were plated on coverslips in 12-well plates, and treated as described for cell 
growth assays. At 48
th
 hour, BrdU (10 μg/ml) was added into cell culture media and cells 
were further incubated for 24 h. The detection of BrdU incorporation was performed as 
described previously [35], except that Alexa Fluor 488-conjugated anti-mouse IgG antibody 
was used for visualization. Cell nuclei were counterstained with DAPI, examined using Zeiss 
Axio Imager.A1 microscope and representative photographs (3–5 frames per coverslip) were 
acquired. Percent BrdU incorporation was calculated after manual counting of BrdU-positive 
(BrdU
+
) and BrdU-negative (BrdU
-
) nuclei. 
Cell cycle analysis 
Analyses were performed as described previously [36]. Briefly, 2.5×10
4
 (for 6-day samples) 
or 10
5
 (for 1 and 3-day samples) SK-BR-3 cells were seeded in 6-well dishes in McCoy’s 5A 
medium. After 36 h incubation, the medium was replaced with fresh McCoy’s 5A medium 
including BH1 or IgG1 isotype control antibody (final 5 μg/ml) ± 1000Unit/ml TNF-α. On 
days 1, 3 and 6 after the addition of antibodies, both suspended and adherent cells were 
collected, fixed and stained with propidium iodide (PI). PI-stained cells were measured and 
analysed by flow cytometry. 
Analysis of the downstream protein expression 
In order to analyze the effect of BH1 treatment on the downstream pathway, SK-BR-3 cells 
were treated for 1–24 h with 10 μg/ml BH1, 1000 Unit/ml TNF-α alone or their combination. 
Cells collected at each time point (1
st
, 2
nd
, 4
th
, 8
th
, 12
th
, 24
th
 hour) were lysed with RIPA 
buffer (containing 1X PhosSTOP). Solubilized proteins were resolved by SDS-PAGE and 
analyzed by immunoblotting. PVDF membranes initially used for detection of phospho-Akt, 
phospho-Erk 1/2 and phospho-HER2 proteins were stripped once (62.5 mM Tris-Cl pH: 6.7, 
2% SDS, 100 mM β-mercaptoethanol), washed thoroughly with TBS-T and re-blotted with 
anti-Akt, anti-Erk 1/2, anti-cyclin D1 and anti-calnexin antibodies. Following incubation with 
HRP-conjugated secondary antibodies to mouse or rabbit IgGs, bound antibodies were 
detected using ECL plus western blot detection kit. 
Statistical analysis 
Experimental data were presented as mean ± SD. Statistical analysis of experiments that have 
been performed at least in triplicate was done using Student’s t test. 
Results 
Novel monoclonal antibodies directed to extracellular domain of HER2 
We used a combined immunization protocol with repeated injections of live SK-BR-3 cells to 
BALB/c mice, followed by a single injection of recombinant HER2 ECD protein. Hybridoma 
clones were screened by HER2 ECD ELISA assay. Five hybridoma clones (namely BH1, 
BH2, BH5, BH6 and BH7) were selected for further analyses, based on their reactivity with 
HER2 ECD, but not EGFR ECD (Additional File 1). All monoclonal antibodies were 
isotyped as IgG1 with κ-light chains. Antibodies were purified from hybridoma supernatants 
using Protein G affinity chromatography and used for further studies. 
Antibody reactivities against breast cancer cell lines 
Anti-HER2 antibodies were tested using five breast cancer cell lines with different ERBB2 
copy numbers. Fluorescence in situ hybridization (FISH) using probes against ERBB2 gene 
and chromosome 17 centromere showed that MCF-7 had three chromosome 17 and two 
ERBB2 signals. MDA-MB-361 provided 4–8 chromosome 17, and 8–12 ERBB2 signals. Both 
SK-BR-3 and BT-474 displayed 5–6 chromosome 17 signals and highly amplified ERBB2 
signals (Figure 1, left panel). Most of T47D cells displayed three chromosome 17 and three 
ERBB2 copies (data not shown). These findings were in perfect agreement with a previous 
study reporting 47, 43, 11 and 2.5 copies of the ERBB2 gene in BT-474, SK-BR-3, MDA-
MB-361 and MCF-7, respectively [37]. When tested by indirect immunfluorescence assay, all 
five anti-HER2 antibodies displayed strong fluorescence intensities with both BT-474 and 
SK-BR-3 cells. The signals obtained with MDA-MB-361 were positive but not strong, but 
those provided by MCF-7 were negative or barely detectable (Figure 1, BH1, BH2, BH5, 
BH6, BH7 panels). 
Figure 1 Strong binding of anti-HER2 antibodies to ERBB2-amplified breast cancer cell 
lines. ERRB2 amplification was analyzed by FISH analysis. Cells were harvested at 
confluence, fixed and subjected to dual-color FISH using Texas Red-labeled ERBB2 (red) 
and FITC-labeled chromosome 17 α-satellite CEP17 (green) DNA probes (left panel). For 
generation of anti-HER2 monoclonal antibodies, mice were immunized with SK-BR-3 cells, 
followed by a recombinant protein composed of extracellular domain of HER2 fused to 
human IgG1 Fc domain (HER2 ECD). Antibodies were purified from conditioned hybridoma 
cell culture media by affinity chromatography. For immunofluorescence assay, cells were 
seeded on coverslips in 6-well plates, incubated 36 h in cell culture medium, fixed, and 
permeabilized. Fixed cells were incubated with anti-HER2 antibodies, and the primary 
antibody binding was detected using Alexa 488- conjugated anti-mouse IgG (BH1, BH2, 
BH5, BH6, BH7 panels; green). Nuclei were counterstained with DAPI (blue) and pictures 
were acquired using Zeiss Axio Imager.A1 microscope 
The binding strengths of antibodies were compared using HER2 ECD ELISA and flow 
cytometry. ELISA test provided evidence of strong binding capacity for BH1, BH6 and BH7 
antibodies. BH5 antibody displayed lowest binding capacity, whereas BH2 had intermediate 
activity. These observations strongly suggested that we produced three anti-HER2 antibodies 
with high affinity, one with low and one with intermediate affinities (Figure 2A). Flow 
cytometric analyses provided similar findings. When tested with T47D breast cancer cell line 
expressing low levels of HER2 [38], BH1 and BH6 displayed highest shifts in staining 
intensity as compared to isotype control antibody. The binding of BH5 was not detectable, 
whereas BH2 displayed a weak binding (Figure 2B). However, when tested with BT-474 that 
has ERBB2 gene amplification (Figure 1, left panel), all antibodies displayed strong intensity 
shifts, BH1 producing the best shift (Figure 2C). 
Figure 2 Binding affinities of anti-HER2 antibodies. (A) HER2 ECD ELISA assay 
showing the binding strengths of five monoclonal antibodies. HER2 ECD-coated plates were 
incubated with increasing concentrations of anti-HER2 antibodies, followed by alkaline 
phosphatase-conjugated anti-mouse IgG antibodies. Y axis shows the absorbance (OD) 
reading at 405 nm following incubation with alkaline phosphatase substrate. T-bars: SD. (B) 
and (C), Flow cytometric analysis of antibody binding to low HER2-expressing T47D (B) 
and high HER2-expressing BT-474 (C) breast cancer cells. Fixed single-cell suspensions 
were incubated with anti-HER2 antibodies, followed by Alexa-488-conjugated secondary 
antibodies and fluorescence intensities were measured using flow cytometry 
Newly generated anti-HER2 antibodies recognize conformation-dependent 
epitopes 
Bioactive antibodies that are most effective against HER2-overexpressing tumors recognize 
conformational epitopes located at ECD subdomains involved in either receptor activation 
[21] or receptor dimerization [23]. Thus, the bioactivity of anti-HER2 antibodies may be 
strongly dependent on how they occupy the critical regions on their target. We performed a 
series of analyses to identify epitopes recognized by newly raised monoclonal antibodies. In 
these studies, Mouse IgG1 isotype antibody and humanized Trastuzumab were used as 
negative and positive controls, respectively. NCL-CB11 (CB11 in short) antibody against 
intracellular domain of HER2 was also used. Initially performed western blot assays using 
different breast cancer cell line lysates provided positive signals with CB11 antibody, but not 
with others (data not shown). Based on these findings, we hypothesized that the epitope(s) 
recognized by our antibodies were unstable under denaturing conditions of SDS-PAGE, 
although they remained stable after paraformaldehyde fixation used in indirect 
immunofluorescence and flow cytometry experiments (Figures 1, 2). Next, we tested whether 
our antibodies were able to immunoprecipitate HER2 from cell lysates made in RIPA buffer. 
Cell lysates made from T47D cells were subjected to immunoprecipitation with our 
antibodies and antibody-bound proteins were tested by western blot assay using CB11 
antibody. All antibodies tested were able to immunoprecipitate HER2 under these conditions. 
The signal obtained with BH5 antibody was weak, as expected (Additional File 2). These 
findings provided evidence that newly generated antibodies recognized conformation-
dependent epitope(s) on endogenously expressed HER2 protein. 
Discovery of a new epitope(s) restricted to the intact form of the extracellular 
domain of HER2 
In order to delineate the epitope(s) recognized by the antibodies, we constructed a series of 
plasmids to express truncated forms of HER2 at its ECD (Figure 3). Huh-7 cells that express 
low levels of endogenous HER2 protein [39] were transiently transfected with plasmids to 
express different forms of HER2, and immunoreactivity of each antibody was tested by 
indirect immunofluorescence and western blotting following immunoprecipitation. In 
immunofluorescence assay, CB11 antibody that was used as a positive control for expression 
of full length and truncated forms of HER2 transgene identified strongly positive transfected 
cells with all plasmids tested (Figure 4, right panel). Another control was Trastuzumab that is 
directed against an epitope located at domain IV of the extracellular region of HER2 [21]. All 
truncated forms of HER2 protein containing domain IV provided strongly positive signals 
with Trastuzumab (Figure 4, Tzm panel). Surprisingly, all five of our antibodies recognized 
only full-length HER2. They did not react with recombinant HER2 protein forms lacking any 
one of the ECD subdomains (Figure 4, panels BH1, BH2, BH5, BH6, BH7). 
Immunoprecipitation-western blotting assays following transient expression of full length and 
four truncated forms of HER2 confirmed immunofluorescence findings (Additional File 3). 
We deduced that newly generated antibodies are directed to an epitope, or closely related 
epitopes present only on structurally intact ECD of HER2. In other words, the reactivity of 
antibodies was lost when any of the four subdomains of the HER2 ECD was deleted. Thus, 
all five antibodies described in the report required the structural integrity of ECD for 
recognition of HER2 receptor (Figure 3). 
Figure 3 Schematic representation of antibody epitope mapping studies. Mammalian 
expression plasmids expressing full-length HER2 (p219D) or partially deleted HER2 were 
transfected into Huh7 cells. Anti-HER2 antibody reactivity was tested by indirect 
immunofluorescence (Figure 4) and immunoprecipitation-western blotting (Additional File 3) 
techniques. The boxes named as I, II, III, IV represent four subdomains of ECD. Grey box: 
transmembrane domain, TK: tyrosine kinase domain, CT: carboxyl-terminal domain. Tzm: 
Trastuzumab.+: antibody reactivity, -: no antibody reactivity. Stars (*) near plasmid names 
indicate that immunofluorescence data were confirmed with immunoprecipitation-western 
blot assay 
Figure 4 Epitope mapping of anti-HER2 antibodies using indirect immunofluorescence 
assay. Huh7 cells were transfected in 6-well plates using a set of mammalian expression 
plasmids encoding full-length or N-terminally truncated HER2 protein. Transfected cells 
were cultivated for 48 h, and subjected to indirect immunofluorescence assay. Transfected 
cells that were recognized by specific antibodies displayed strong green fluorescence. The 
letters from (a) to (k) indicate the plasmids in the following order: pDEST26 (empty vector), 
p219D, pCC2001, pCC2005, pCC2004, pCC2003, pCC2002, pCC2008, pCC2007, 
pCC2006, pCC2012 (see Figure 3 for description of HER2-expression plasmids). (−) No 
primary antibody, Tzm: Trastuzumab, CB11: a monoclonal antibody recognizing an epitope 
at intracellular domain of HER2 that was used as a positive control for expression of 
transfected plasmids 
Effect of anti-HER2 antibodies on cell growth 
The bioactivity of antibodies was first tested against SK-BR-3 cells. Affinity purified anti-
HER2 antibodies were added at increasing concentrations into the culture media and relative 
cell growth was tested following 6 days of cell culture. Only BH6 and BH1 antibodies 
displayed modest but significant inhibitory effect on target cells, by lowering relative cell 
growth to 65% and 73% respectively, as compared to isotype control antibody (Figure 5A; 
p < 0. 006 at 10 μg/ml antibody concentration). In contrast, BH2, BH5 and BH7 antibodies 
did not affect the growth of SK-BR-3 cells. 
Figure 5 Anti-HER2 antibodies exhibit enhanced anti-growth effect in the presence of 
tumor necrosis factor-α in SK-BR-3 cells. (A) SK-BR-3 cells were plated onto 96-well 
plates and incubated at 37°C with 5% CO2. After 2 h of incubation, antibodies (0–10 μg/ml) 
were added, and cells were incubated for 6 days. (B) Antibodies (0–10 μg/ml) were added as 
described in (A), and cells were incubated for 4 h prior to TNF-α (1000 U/ml) addition to the 
culture medium. Cells amount was determined by Sulforhodamine B assay after 6 days of 
treatment. T. Bars, SD; * p < 0.006, ** p < 0.0005, (A, B) 
Effects of anti-HER2 antibodies in combination with tumor necrosis factor-α 
It has been previously reported that amplified expression of HER2 in breast cancer cells 
induces resistance to TNF-α cytotoxicity [40,41] that can be sensitized by Trastuzumab [42]. 
Therefore, we asked whether our anti-HER2 antibodies were able to sensitize SK-BR-3 cells 
to TNF-α. We performed antibody treatment experiments in the presence of 1000 U/ml of 
TNF-α (Figure 5B). In the absence of antibody, TNF-α alone induced nearly 50% growth 
inhibition. This effect was not modified significantly in the presence of increasing 
concentrations of IgG1 isotype control antibody (up to 10 μg/ml tested). In sharp contrast, all 
five anti-HER2 antibodies strongly enhanced TNF-α-induced growth inhibition (p < 0.0005 at 
10 μg/ml antibody concentration). As little as 0.25 μg/ml anti-HER2 antibody was sufficient 
to significantly enhance TNF-α-mediated growth inhibition, as compared to IgG1 isotype 
control antibody at the same concentration (p < 0.005). Only one antibody, namely BH7, 
displayed a slightly weaker enhancer activity, reaching significance at 1.25 μg/ml 
concentration (p <0.02). Enhancer effects of anti-HER2 antibodies were nearly saturated at 
2.5 μg/ml concentration, reaching to 80-90% growth inhibition depending on antibody 
(Figure 5B). 
Cell-dependent interactions between anti-HER2 antibodies and tumor 
necrosis factor-α creating both synergistic and antagonistic growth effects 
Based on observations with SK-BR-3 cells, we analyzed interactions between anti-HER2 
antibodies and TNF-α, using five different breast cancer cell lines. We compared growth 
responses to (i) 5 μg/ml of each individual antibody, (ii) 1000 U/ml of TNF-α, and (iii) 5 
μg/ml antibody and 1000 U/ml of TNF-α in combination. An interaction score for each 
combination was calculated as described in the Methods, where a score of 1 means no 
interaction, or independence; a score smaller than 1 means synergy, and a score larger than 1 
means antagonism [32]. In Figure 6, we analyzed TNF-α and anti-HER2 antibody 
interactions as compared to IgG1 isotype control antibody. IgG1 control antibody interactions 
with TNF-α provided scores between 0.81-0.88. Therefore, we considered values between 
0.8-1.2 as an indication of non-interaction. When tested with SK-BR-3 cell line, interaction 
scores obtained for TNF-α and new anti-HER2 antibody combinations ranged between 0.26 
and 0.48 (Figure 6, top). Synergy scores obtained with BH1, BH2 and BH5 were particularly 
strong (scores: 0.35, 0.30 and 0.26, respectively). In contrast, there was no interaction 
between Trastuzumab and TNF-α (score = 0.95). Thus, all five new anti-HER2 antibodies 
acted synergistically with TNF-α to inhibit the growth of SK-BR-3 cells. 
Figure 6 Synergy and antagonism between anti-HER2 antibodies and tumor necrosis 
factor-α. Anti-Her2 antibodies and TNF-α acted synergistically in SK-BR-3 cells (top), but 
antagonistically in BT-474 cells (bottom). Growth effects observed under antibody (white 
columns), TNF-α (striped columns), and antibody + 1000 TNF-α (black columns) were 
obtained as follows. Cells were plated onto 96-well plates and incubated at 37°C with 5% 
CO2. After 2 h of pre-incubation, antibodies (5 μg/ml) were added, and cells were incubated 
for 6 days to study the effects of antibodies alone (white columns). The effects TNF-α (1000 
U/ml) alone (striped columns) were studied by adding this cytokine into cell culture medium 
after 4 h of pre-incubation. For combined treatments, antibodies (5 μg/ml) and TNF-α (1000 
U/ml) were added after 2 h and 4 h of pre-incubations, respectively (black columns). Cells 
amount was determined by Sulforhodamine B assay after 6 days of treatment. Growth level 
under a drug condition was defined as the growth under that condition normalized by growth 
under no drug condition. Expected growth level under no interaction (gray columns) was 
calculated by multiplying the growth levels under each individual drug. The observed growth 
level for each combination was divided by the expected growth level to find an interaction 
score according to Bliss Independence Model for drug interactions (displayed under each 
antibody label). The combination of TNF-α with isotype control antibody (IgG1) or 
Trastuzumab (Tzm) provided scores near 1, meaning no interaction or independence in both 
cell lines. New anti-HER2 antibodies provided scores less than 0.57 in SK-BR-3 cells, 
meaning synergy. In contrast their interaction scores were more than 1.40 in BT-474 cells, 
meaning antagonism 
Further studies indicated that the interaction between anti-HER2 antibodies and TNF-α was 
cell-dependent. Indeed, we observed a completely opposite response with another breast 
cancer cell line, namely BT-474 (Figure 6, bottom). This cell line responded to a few anti-
HER2 antibodies modestly albeit significantly (BH1, p < 0.05; Tzm, p < 0.003). The response 
to TNF-α alone was about 50% growth inhibition, as observed with SK-BR-3 cells. Novel 
anti-HER2 antibodies abolished TNF-α-induced growth inhibition either completely (BH1, 
BH2, BH5, BH7) or partially (BH6) in BT-474 cells. Interactions scores of novel anti-HER2 
antibodies ranged between 1.40 and 3.08, all indicative of an antagonistic interaction with 
TNF-α. Again, Trastuzumab had no major interaction with TNF-α (score = 1.21). Data on 
interaction analyses performed with MDA-MB-361, MCF-7 and T47D were shown in 
Additional File 4. When tested alone with MDA-MB-361 cells, some antibodies (BH1, BH2, 
BH7) displayed significant growth inhibition (>50% inhibition, p < 0.0003). Trastuzumab had 
no detectable anti-growth effect, but BH5 and BH6 displayed only modest activity (27% and 
35% growth inhibition, respectively; p < 0.02). TNF-α was highly toxic to this cell line 
causing >95% growth inhibition. Antibody co-treatments rescued TNF-α induced growth 
inhibition only slightly. Thus, drug interaction analysis was not conclusive. The growth of 
MCF-7 cells did not appear to be affected by antibody treatment. In contrast, these cells were 
the most sensitive ones to TNF-α with nearly 100% growth inhibition. Antibody co-
treatments did not change their response to TNF-α. T47D cells were resistant to both anti-
HER2 antibody and TNF-α treatments, either alone or in combination. 
Detailed analysis of interaction between BH1 antibody and tumor necrosis 
factor-α 
Drug interaction analyses described above were performed using fixed amounts of antibodies 
and TNF-α. We obtained clear-cut results with only SK-BR-3 and BT-474 cells. Therefore, 
we decided to test the effects of combined treatment of anti-HER2 antibody BH1 and TNF-α 
on four breast cancer cell lines using a checkerboard assay. BH1 was selected as a 
representative of newly generated anti-HER2 antibodies. Each cell line was grown on a 7×8 
grid of BH1 antibody and TNF-α combinations. The concentration of TNF-α was increased 
on the x-axis (0, 8, 16, 32, 62.5, 125, 250 and 500 U/ml) and the concentration of BH1 
antibody was increased on the y axis (0, 0.16, 0.312, 0.625, 1.25, 2.5 and 5 μg/ml). Such an 
experimental setting allowed us to measure the growth of each cell type in 42 concentration 
combinations of BH1 antibody and TNF-α, in addition to the growth of cells under each 
‘drug’ alone. This experiment was done in triplicate for each cell type. The average growth 
measures are shown in Figure 7. We analyzed the growth measures using the same definition 
of drug synergy based on Bliss Independence Model as described above. We found 
concentration combinations where BH1 and TNF-α are significantly synergistic or 
antagonistic, which are indicated as green or blue dots on Figure 7, respectively. For each of 
the drug interaction experiments, we next computed a single interaction score as described 
previously [34]. These scores, which are interpreted as described above, are shown in Figure 
7. According to this, BH1 and TNF-α exhibited synergy in SK-BR-3 cells, while they were 
antagonistic in BT-474 and MDA-MB-361 cell types, when all concentration combinations 
are considered. Interestingly, BH1 antibody, even at a very low dose (0.16 μg/ml), strongly 
suppressed the growth inhibition triggered by TNF-α in BT-474 cells. These observations 
confirm strong synergistic and antagonistic interactions of TNF-α and anti-HER2 antibodies 
in SK-BR-3 and BT-474, respectively (Figure 6). The interaction score for MCF-7 was very 
close to 1, suggesting independence. 
Figure 7 Anti-HER2 antibody and tumor necrosis factor-α interaction is cell type-
specific. The growth of breast cancer cell lines under various combinations of BH1 antibody 
(0, 0.161, 0.312, 0.625, 1.25, 2.5, 5.0 μg/ml) and TNF-α (0, 8, 16, 32, 62.5, 125, 250, 500 
U/ml) treatments was experimentally tested in triplicate and the average relative growth 
levels were calculated. Heatmap represents the cell growth (as measured by OD) under 
different conditions. Synergistic and antagonistic interactions are indicated by green and blue 
dots, respectively. Numbers associated with cell line names indicate interaction scores. 
According to this checkerboard assay, BH1 and TNF-α show synergy in SK-BR-3 cells, but 
antagonism in BT-474 and MDA-MB-361 cells. There is no interaction in MCF-7 cells 
Mechanisms of growth inhibition by anti-HER2 antibodies and tumor 
necrosis factor-α 
In cancer cells, overexpressed HER2 is believed to be constitutively active as homodimers 
and/or as heterodimers with ligand-dependent HER3 [6]. Downstream signaling from HER2 
involves PI3K-dependent activation of Akt and Ras-dependent activation of ERK1/ERK2 
proteins by phosphorylation, mediating cell survival and proliferation activities of HER2 [6]. 
Therapeutically relevant Trastuzumab and Pertuzumab antibodies inhibit both Akt and 
ERK1/ERK2 phosphorylation, leading to growth inhibition [24,43-45]. TNF-α signaling 
generates both cell survival and apoptosis signals, depending on the activation of NFκB 
transcription factor [46]. We further investigated the mechanisms of growth inhibition in 
responsive SK-BR-3 cells. As shown in Figure 8 left panel, untreated SK-BR-3 cells 
displayed relatively stable expression of phospho-HER2, phospho-Akt, total Akt, phospho-
Erk1/2 and total Erk1/2. Cyclin D1 levels were undetectable under this experimental 
condition. Cells treated with 10 μg/ml BH1 antibody inhibited Akt phosphorylation that was 
clearly detectable between 8 h and 24 h of treatment. There was also a partial inhibition of 
Erk1/2 phosphorylation between 4 h and 24 h of treatment. In parallel with these changes, we 
also observed progressive accumulation of cyclin D1 levels detected as early as 4 h of 
treatment. In contrast, HER2 phosphorylation was not affected by antibody treatment (Figure 
8 middle panel). Cells co-treated with 10 μg/ml BH1 and 1000 U/ml TNF-α displayed 
essentially the same type of alterations (Figure 8 right panel). Thus, TNF-α appeared not to 
modify the effects of the anti-HER2 antibody on phospho-Akt, phospho-ERK1/2 and Cyclin 
D1 in SK-BR-3 cell line. Indeed, treatment of cells with 1000 U/ml TNF-α alone did not 
affect any of the parameters studied, except a delayed inhibition of Akt phosphorylation at 24 
h (Additional File 5). 
Figure 8 In vitro molecular responses of SK-BR-3 cell to anti-HER2 antibody BH1 and 
tumor necrosis factor-α. SK-BR-3 cells were treated up to 24 h with BH1 antibody (10 
μg/ml), TNF-α (1000 U/ml) or the combination of both agents. Cell lysates were prepared 
from cells harvested at indicated times (hr, hours) and the expressions of phospho-HER2 
(pHER2), phospho-Akt (pAkt), total Akt (Akt), phospho-ERK1/phospho-Erk2 (pErk1/2), 
total Erk1/Erk2 (Erk 1/2) and Cyclin D1 were analyzed by western blotting. Calnexin was 
used as a loading control. Untreated cells were incubated in a parallel experiment in the 
absence of any treatment 
Cyclin D1 accumulates in G1 and G2 phases of cycling cells with a loss of expression in S 
phase cells [47]. Accordingly, Cyclin D1 accumulation could indicate progressive 
accumulation of cells at G1 and G2/M phases under anti-HER2 antibody treatment. We tested 
this hypothesis by exposing BH1 and/or TNF-α-treated cells to BrdU labeling and cell cycle 
analysis experiments during 6 days of treatment. Tests were performed at days 1, 3 and 6 
(Figure 9A). SK-BR-3 cells have doubling times varying between 15 h and 36 h [48,49]. In 
order to detect the ratio of cells at G1/G0 phase, we used a modified DNA labeling protocol 
by exposing cells to BrdU for 24 h prior to each experimental time. As compared to IgG1 
isotype control antibody, BH1 induced a significant decrease in the number of BrdU
+
 cells at 
days 3 and 6 (p ≤ 0.05). Treatment of cells with IgG1 and TNF-α resulted in a more 
pronounced decrease of BrdU
+
 cells that dropped progressively to 35% at day 6. When 
compared to IgG1 + TNF-α-treated cells, BH1 + TNF-α-treated cells responded immediately 
by a radical decrease of BrdU incorporation rates to 25% and 26% at days 1 and 3, 
respectively (p ≤ 0.05). However, this inhibition was not stable and reversed to 37% at day 6 
(Figure 9A). These findings indicated that both BH1 and TNF-α significantly increased the 
number of cells at G1/G0 phase, although this effect was delayed in BH1-only treatment. 
Sharp and immediate decrease in BrdU (+) cells with BH1 + TNF-α co-treatment confirmed 
the synergy between BH1 and TNF-α in these cells. Cell cycle analyses confirmed these 
findings (Figure 9B-D). As compared to IgG1 isotype control antibody-treated cells, BH1-
treated cells first showed an increase in G2 cells at day 1, followed by a progressive increase 
of G1 cells at days 3 and 6. This was accompanied with a decrease in S phase cells. TNF-α 
treatment resulted in an immediate and stable response with an increase in G1 cells, 
concomitant with a decrease of S phase cells at all time points tested. BH1 + TNF-α treatment 
exaggerated this response, leading to a stronger accumulation of G1 phase cells, associated 
with a depletion of G2 phase cells. We concluded that both BH1 antibody and TNF-α were 
able to induce sustained accumulation of SK-BR-3 cells at G1/G0 phase, and their 
combination amplified this response particularly in early times of co-treatment. 
Figure 9 Effects of anti-HER2 antibody BH1 and tumor necrosis factor-α on DNA 
synthesis and cell cycle in SK-BR-3 cells. (A) Effects on DNA synthesis were tested by 24-
h BrdU incorporation assay. Cells were plated on coverslips in 12-well plates, treated as 
described in Figure 5, and were exposed to BrdU during 24 h prior to indicated days. Nuclear 
BrdU was detected by indirect immunofluorescence assay. Nuclei were counterstained with 
DAPI, examined using Zeiss Axio Imager.A1 microscope. Representative photographs (3–5 
frames per coverslip) were acquired. Percent BrdU incorporation was calculated after manual 
counting of BrdU
+
 and BrdU
-
 nuclei. * Denotes p-values ≤ 0.05 (BH1 vs. IgG1, BH1 + TNF-α 
vs.IgG1 + TNF-α). T-bars: SD. (B-D). Effects on cell cycle were analyzed by flow cytometry. 
SK-BR-3 cells were treated with 20 μg/ml BH1 or IgG isotype control antibody in the 
presence or absence of 1000 U/ml TNF-α. Cells were fixed on day 1 (B), day 3 (C) and day 6 
(D), stained with propidium iodide and the cell cycle distribution was analysed with flow 
cytometry. Fraction of cells present in G2/M-phase (G2/M), S-phase (S) and G1-phase (G1) 
are shown in purple, green and orange respectively. Fraction of apoptotic cells observed as a 
SubG1 peak is shown in black 
Discussion 
This report describes five novel anti-HER2 monoclonal antibodies that have been produced 
by immunizing mice with HER2-overexpressing whole cells, followed by a boost with 
recombinant HER2 ECD homodimer protein. Immunoprecipitation and western 
immunoblotting studies indicated that all five antibodies were directed against conformation-
dependent epitope(s) present on the endogenous HER2 protein. Epitope mapping with 
recombinant HER2 protein forms that have been truncated at ECD domain indicated that all 
five antibodies react only with the native form of cellular HER2, being unable to recognize 
truncated proteins lacking any of the four subdomains. Although we do not yet know whether 
our antibodies recognize identical, overlapping or independent epitopes on the intact ECD 
domain, it is evident that their epitope(s) is different from those recognized by Trastuzumab 
and Pertuzumab. Trastuzumab, a therapeutic antibody already approved for clinical use, 
recognizes an epitope restricted to subdomain IV, involved in receptor activation [21]. 
Pertuzumab, a therapeutic antibody tested in different clinical trials, recognizes a distinct 
epitope located on subdomain II, involved in receptor dimerization [23]. Antibodies directed 
to ECD epitope(s) different from other anti-HER2 therapeutic antibodies may serve as new 
analytical tools to study the structural organization of HER2 at the cell surface that may be 
present as monomers, homodimers and heterodimers depending on cell type and extracellular 
environment such as the availability of ligands that activate heterodimer partners of HER2. 
Dynamic changes at the receptor ECD in relation with transcriptional, translational and post-
translational modifications can be monitored with these antibodies, both biochemically and 
biologically. 
In vitro effects of novel anti-HER2 antibodies were tested against five different breast cancer 
cell lines displaying different degrees of ERBB2 amplification and HER2 expression. 
Individually tested novel anti-HER2 antibodies were weakly effective as growth inhibitors 
(Figure 6). This was not surprising. Indeed, Trastuzumab (4D5) has a modest growth 
inhibitory effect (56%), and Pertuzumab (2C4), the best therapeutic alterative to 
Trastuzumab, induces only 20% growth inhibition [42]. Based on the synergy between 
Trastuzumab and Pertuzumab directed to different epitopes of HER2 [24], we performed 
studies to test combinatory anti-growth effects of our anti-HER2 antibodies with 
Trastuzumab on SK-BR-3 cells. Preliminary data suggested a synergy between them, raising 
the possibility that our antibodies may be combined with Trastuzumab or Pertuzumab to 
enhance anti-cancer activity. This will be the focus of further work. 
The most striking feature of novel anti-HER2 antibodies was their differential interaction 
with TNF-α depending on cell type. They synergized with TNF-α on SK-BR-3 cells by 
raising growth inhibition from 50% to nearly 90%. In sharp contrast, the same antibodies 
displayed strong antagonism with TNF-α on BT-474 cells and MDA-MB-361 cells by 
abolishing TNF-α-induced growth inhibition either completely (BT-474 cells) or partially 
(MDA-MB-361 cells). Trastuzumab did not have any synergistic or antagonistic effects on 
TNF-α-mediated growth inhibition in these cell lines (Figure 6). The sensitization of SK-BR-
3 cells to TNF-α cytotoxicity by mouse monoclonal antibody 4D5 (from which Trastuzumab 
has been humanized) has been reported [42], but there is no previous data on synergy or 
antagonism between anti-HER2 antibodies and TNF-α, to our best knowledge. 
TNF-α is one of the most potent anti-tumor factors when used at high concentrations, but its 
systematic toxicity hampers its clinical applications [50]. The sensitization of SK-BR-3 cells 
to TNF-α with anti-HER2 antibodies provides experimental evidence for combination of low 
TNF-α doses with anti-HER2 antibody treatment to achieve effective anti-growth effects. 
Based on checkerboard analyses reported in Figure 7, a synergistic anti-growth response 
could be obtained from SK-BR-3 cells with as low as 32 U/ml TNF-α under in vitro 
conditions. But, one caveat is that the same antibody-TNF-α combination could produce 
completely opposite responses in other cells, as reported here for BT-474 and MDA-MB-361 
cells. For example, as little as 0.1 mg/ml BH1 antibody was able to abolish TNF-α 
cytotoxicity in BT-474 cells. 
The mechanisms of differential responses of breast cancer cell lines to combined treatment 
with anti-HER2 antibody and TNF-α merit further investigation. Here, we investigated the 
mechanisms of growth response of SK-BR-3 cells to combined treatment. The analysis of 
several downstream targets of HER2 signaling indicated that BH1 antibody did not inhibit 
HER2 phosphorylation, yet it was able to inhibit the phosphorylation of Akt and ERK1/2 
kinases. These changes resulted in a progressive increase of cyclin D1 protein levels. DNA 
synthesis was inhibited and cells accumulated progressively at G1 phase of the cell cycle. 
The addition of TNF-α to BH1 treatment dramatically enhanced these responses leading to an 
immediate and stable growth arrest. 
Conclusions 
Newly generated anti-HER2 monoclonal antibodies allowed the identification of a novel 
epitope on HER2 receptor that is restricted to the intact form of its ECD. These antibodies 
displayed cell type-dependent interactions with TNF-α, resulting in synergistic, antagonistic 
or independent anti-growth effects. The synergistic activity was associated with inhibition of 
Akt and ERK1/2 phosphorylation leading to immediate and stable cell cycle arrest. 
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Additional_file_1 as PDF 
Additional File 1 Anti-HER2 antibodies did not react with EGFR. Mice were immunized 
with SK-BR-3 cells, followed by a recombinant protein composed of extracellular domain of 
HER2 fused to human IgG1 Fc domain (HER2 ECD). ELISA plates that have been coated 
with either HER2 ECD or EGFR ECD were incubated with antibody-containing hybridoma 
supernatants, followed by alkaline phosphatase-conjugated anti-mouse IgG antibodies. The Y 
axis shows the absorbance (OD) reading at 405 nm following incubation with alkaline 
phosphatase substrate (assays in duplicate). 
Additional_file_2 as PDF 
Additional File 2 Antibody binding to endogenously expressed HER2 protein as tested 
by immunoprecipitation-western blot assay. T47D-derived lysates were subjected to 
immunoprecipitation with different anti-HER2 antibodies. Antigen-antibody complexes were 
captured onto Protein G-conjugated beads, eluted and subjected to western blot assay using 
CB11 antibody. Blots were overexposed to visualize the weakly positive HER2 
immunoprecipitated by BH5 antibody. Tzm: Trastuzumab used as a positive control 
antibody. (−): No primary antibody. 
Additional_file_3 as PDF 
Additional File 3 Epitope mapping of anti-HER2 antibodies using combined 
immunoprecipitation-western blot assay. Huh7 cells were transfected in 6-well plates 
using a set of mammalian expression plasmids encoding full-length or N-terminally truncated 
HER2 protein. Transfected cells were cultivated for 48 h; cell lysates were subjected to 
immunoprecipitation with different anti-HER2 antibodies. Antigen-antibody complexes were 
captured onto Protein G-conjugated beads, eluted and subjected to western blot assay using 
CB11 antibody. Arrows: immunoreactive bands specific for full-length and truncated HER2 
protein forms. IP: immunoprecipitation; *: non-specific bands originating from antibodies 
used for immunoprecipitation. 
Additional_file_4 as PDF 
Additional File 4 Interaction between anti-HER2 antibodies and tumor necrosis factor-
α. MDA-MB-361 cells were partially sensitive to anti-HER2 antibodies, but highly sensitive 
to TNF-α (top). MCF-7 cells were resistant to anti-HER2 antibodies, but highly sensitive to 
TNF-α (middle). T47D cells were resistant to both anti-HER2 antibodies and TNF-α 
(bottom). Growth measurements observed under 5μg/ml antibody (white columns), 1000 
U/ml TNF-α (striped columns), and 5 μg/ml antibody + 1000 U/ml TNF-α (black columns) 
were obtained experimentally, as described in Figure 6. Growth level under a drug condition 
was defined as the growth under that condition normalized by growth under no drug 
condition. Expected growth level under no interaction (gray columns) was calculated by 
multiplying the growth levels under each individual drug. The observed growth level for each 
combination was divided by the expected growth level to find an interaction score according 
to Bliss Independence Model for drug interactions. Interaction scores were not calculated for 
these cell lines. 
Additional_file_5 as PDF 
Additional File 5 In vitro molecular responses of SK-BR-3 cells to tumor necrosis 
factor-α. SK-BR-3 cells were treated up to 24 h with TNF-α (1000 U/ml). Cell lysates were 
prepared from cells harvested at indicated times (hr, hours) and the expressions of phospho-
HER2 (pHER2), phospho-Akt (pAkt), total Akt (Akt), phospho-ERK1/phospho-Erk2 
(pErk1/2), total Erk1/Erk2 (Erk 1/2) and Cyclin D1 were analyzed by western blotting. 
Calnexin was used as a loading control. 
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